Implications of cardiovascular outcome trials with injectable antidiabetic agents
نویسندگان
چکیده
منابع مشابه
Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis
Since the rosiglitazone controversy, the US Food Drug Administration (USFDA) in the year 2008, mandated that all new antidiabetic agents must undergo an adequately powered, glycemic‐equipoised, cardiovascular (CV) outcome trial (CVOT) in high‐risk Type 2 diabetic patients, during postmarketing phase to demonstrate its safety by showing noninferiority against placebo. While noninferiority was de...
متن کاملCardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues
The prevalence of type 2 diabetes mellitus (T2DM) has increased rapidly over the past decade. In the Untied States, this increase has been greater than 40%. Obesity, which is closely linked to risk of developing T2DM, has likewise increased in prevalence by more than 60% during the same time period. Cardiovascular disease is the major cause of mortality among patients with T2DM, accounting for ...
متن کاملUpdates on cardiovascular outcome trials in diabetes
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials...
متن کاملResults from Cardiovascular Outcome Trials in Diabetes.
Los pacientes con diabetes mellitus tipo 2 (DM2) tienen un riesgo de enfermedad cardiovascular (ECV) elevado tanto por la hiperglucemia como por otros factores de riesgo vascular asociados y, además, un peor pronóstico ante los eventos cardiovasculares. La diabetes acentúa la gravedad de todas las fases de la aterosclerosis, su desarrollo y sus complicaciones. En los pacientes con diabetes exis...
متن کاملCombining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease
Patients with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular disease (CVD). Unfortunately, several potential barriers exist for CVD risk management in diabetes, including the need for significant lifestyle changes, potential problems with hypoglycemia, weight gain, injection tolerability, treatment complexity with current diabetes therapies and other, unmodifiable fact...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes
سال: 2018
ISSN: 1753-0393
DOI: 10.1111/1753-0407.12792